◼ Archived
Health
🔮 fades ✓
GLP-1
29 independently sourced, verified news trends involving GLP-1.
Coverage evidence
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 2 news categories, from Jun 25, 2026 through Oct 3, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
◼ Archived
Health
🔮 holds ✗
Does GLP-1 use result in significant hair loss?
◼ Archived
Business
🔮 holds ✗
McDonald's is exploring ways to attract GLP-1 users
◼ Archived
Business
🔮 holds ✗
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
◼ Archived
Business
🔮 holds ✗
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
◼ Archived
Business
🔮 fades ✓
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
◼ Archived
Business
🔮 holds ✗
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
◼ Archived
Health
🔮 holds ✗
What Really Disappears When You Lose Weight on GLP-1 Drugs?
◼ Archived
Health
🔮 holds ✗
GLP-1 drugs dubbed ‘fountain of youth’ as doctors share surprising benefits beyond weight loss
◼ Archived
Health
🔮 fades ✓
Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
◼ Archived
Health
🔮 fades ✓
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.
◼ Archived
Health
🔮 holds ✗
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
◼ Archived
Health
🔮 holds ✗
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
◼ Archived
Business
🔮 holds ✗
Compounded GLP-1 drugs creating concern among doctors and FDA
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
◼ Archived
Health
🔮 holds ✗
Weight-loss jab users warned about relationship side effect no one prepares you for
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.
◼ Archived
Health
🔮 holds ✓
Scientists Searching 6,000 Drugs For Anti-Aging Properties Found One Hiding in Plain Sight
Researchers identify existing medications, including GLP-1 drugs and nasal sprays, as potential candidates for slowing biological aging processes.
◼ Archived
Health
🔮 holds ✗
Rare eye disorder linked to Ozempic-like medications
Regulators and health advisors are warning of a rare but severe risk of vision loss associated with GLP-1 weight-loss medications.
◼ Archived
Health
🔮 fades ✗
GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds
A new economic study suggests a correlation between the use of GLP-1 weight-loss drugs and a 17% reduction in employee sick leave.
◼ Archived
Business
🔮 holds ✓
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
◼ Archived
Health
🔮 holds ✓
24 GLP-1 Users Reveal The Good, The Bad, And The Shocking Side Effects
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
◼ Archived
Health
🔮 holds ✗
Does stopping a GLP-1 really doom you to regain all the weight?
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
◼ Archived
Business
🔮 holds ✗
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Rising demand for GLP-1 weight-loss medications is straining budgets and prompting insurers and employers to limit coverage.
◼ Archived
Health
🔮 holds ✗
New weight loss pill that’s beating oral Ozempic
New oral GLP-1 receptor agonists are emerging as powerful alternatives to existing weight-loss medications in recent clinical trials.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.
◼ Archived
Business
🔮 holds ✓
Delta rolls out new basic business, premium economy tickets
Delta Air Lines is introducing new, lower-cost ticket options for business and first-class cabins that come with reduced amenities.
◼ Archived
Health
🔮 fades ✗
Amid heat wave, doctors warn of health risks for people taking GLP-1 drugs
Medical professionals are warning patients on GLP-1 medications about increased health risks during the current heat wave.
◼ Archived
Business
🔮 holds ✓
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
◼ Archived
Health
🔮 holds ✗
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.